Black checkmark with a sparkle and a curved line underneath on a white background.
Company

Decoy Therapeutics Inc.

Ticker
DCOY
Sector
Industry
Report date
November 12, 2026
Valye AI Score

94

Very high visibility
Recent developments
Recent developments summary

Recent developments highlight Decoy Therapeutics' progress in antiviral and pan-filovirus therapeutic programs, strategic partnerships, and regulatory pathway advancements.

Recent developments:
  • Decoy Therapeutics reported preclinical data supporting its weekly intranasal antiviral candidate DCOY-CoV [N1].
  • The company expanded its pan-filovirus therapeutic efforts through an FDA regulatory pathway [N2].
  • Decoy Therapeutics partnered with HVIVO to advance its D-MAV candidate into clinical studies [N5].
  • The company reached a global access commitment agreement with the Gates Foundation to broaden therapy availability [N6].
  • Decoy Therapeutics completed a merger with Salarius Pharmaceuticals and changed its name in early 2026, following reverse stock splits in 2025 and 2026 [S1].
  • The company faces regulatory risks related to Nasdaq's new $5 million market value listing standard, which could lead to delisting if implemented [S2].
Overview

Decoy Therapeutics Inc. operates in the biotechnology sector focusing on innovative therapeutics targeting viral infections and cancer. The company completed a merger with Salarius Pharmaceuticals in November 2025 and subsequently changed its name to Decoy Therapeutics Inc. It maintains a board of directors with extensive experience in pharmaceutical development and corporate governance. The company reported modest revenues and a net loss in its latest quarterly filing, reflecting ongoing investment in research and development. Its pipeline includes a weekly intranasal antiviral candidate (DCOY-CoV) and pan-filovirus therapeutic programs. Decoy Therapeutics has engaged in partnerships to advance clinical studies and has committed to global access agreements to broaden therapy availability. The company has also undertaken reverse stock splits as part of its capital structure management.

Executive summary

Decoy Therapeutics Inc. is a biotechnology company engaged in developing antiviral and cancer therapeutics, with recent corporate restructuring through a merger and name change completed in late 2025. The company reported $8.17 million in cash and cash equivalents and a net loss of approximately $2.99 million for the quarter ended September 30, 2026. It has active development programs including a weekly intranasal antiviral candidate and expanded pan-filovirus efforts through FDA pathways. The company faces regulatory risks related to Nasdaq listing standards. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.

Scenarios for DCOY

Bull case model:

Decoy Therapeutics has demonstrated progress in its antiviral and pan-filovirus therapeutic programs, including preclinical data for its weekly intranasal DCOY-CoV candidate and expansion through FDA pathways. Partnerships to advance clinical studies and global access commitments indicate strategic execution. The company's experienced leadership and board may facilitate efficient development and commercialization efforts. Its liquidity position provides operational runway to support ongoing research and development activities.

Bear case model:

The company reported a net loss and negative earnings per share in its latest quarter, reflecting ongoing expenses without significant revenue generation. Regulatory risks related to Nasdaq's new market value listing standards could impact its stock listing status. The biotech sector's inherent risks include clinical trial failures, regulatory hurdles, and capital market challenges. Reverse stock splits may indicate past challenges in maintaining share price levels. The company's future depends on successful clinical development and regulatory approvals, which are uncertain and may affect its financial stability and market presence.

Moat:

Decoy Therapeutics' moat is primarily based on its proprietary therapeutic candidates targeting viral diseases and cancer, supported by preclinical and clinical development programs. Its strategic partnerships and global access commitments may enhance its competitive positioning. The company's leadership team and board bring significant industry experience, which supports its ability to navigate regulatory pathways and advance its pipeline. However, as a clinical-stage biotech company, its moat is contingent on successful development and regulatory approvals, which remain uncertain.

Risks overview
Risks summary
The most significant risk is the potential delisting from Nasdaq due to new market value listing standards, which could materially affect the company's capital access and investor confidence.
Risks details:

• Nasdaq Listing Risk: The SEC-approved Nasdaq market value listing standard requires a minimum $5 million market value of listed securities. If implemented, Decoy Therapeutics' current market capitalization may fall below this threshold, risking immediate delisting without cure periods, which could adversely affect investor confidence and liquidity [S2].
• Clinical Development Risk: As a clinical-stage biotechnology company, Decoy Therapeutics faces risks inherent to drug development, including potential failure in clinical trials, regulatory delays, or inability to obtain approvals for its therapeutic candidates.
• Financial Risk: The company reported a net loss and negative earnings per share, indicating ongoing operating losses. Continued funding requirements may lead to dilution or increased costs, impacting shareholder value.

FINAL FORECAST FOR DCOY

Final take one line
Decoy Therapeutics is a clinical-stage biotech company with active antiviral and cancer therapeutic programs, supported by recent preclinical data and partnerships, but faces Nasdaq listing risks and ongoing development challenges.
Final take 12 to 24 month view

Business trends: Progress in antiviral and pan-filovirus therapeutic development with strategic partnerships and global access commitments.
Execution milestones: Advancement of clinical studies including D-MAV candidate, regulatory pathway navigation, and integration post-merger.
Key risks: Potential Nasdaq delisting due to market value standards, clinical development uncertainties, and financial sustainability challenges.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

94
LLM visibility overview
LLM Visibility known facts
  • Decoy Therapeutics Inc. is a biotechnology company focused on developing therapeutics, including antiviral and cancer therapies.
  • The company completed a merger with Salarius Pharmaceuticals in November 2025 and changed its legal name to Decoy Therapeutics Inc. in January 2026.
  • Decoy Therapeutics has a board of directors with experienced members from pharmaceutical and biotech industries, including a CEO with over 20 years of biotech leadership experience [S1].
  • The company reported cash and cash equivalents of approximately $8.17 million as of September 30, 2026, with current assets of about $8.38 million and current liabilities of approximately $4.25 million, resulting in a current ratio of 1.97 and a cash ratio of 1.92 [S2].
  • For the quarter ended September 30, 2026, Decoy Therapeutics reported revenues of $307,430 and a net loss of approximately $2.99 million, with basic and diluted EPS of -3.53 USD per share [S2].
  • The company is developing an intranasal weekly antiviral candidate DCOY-CoV and has reported preclinical data supporting this program [N1].
  • Decoy Therapeutics is expanding its pan-filovirus therapeutic efforts through an FDA regulatory pathway [N2].
  • The company has engaged in partnerships to advance clinical studies, including collaboration with HVIVO to advance its D-MAV candidate [N5].
  • Decoy Therapeutics has reached a global access commitment agreement with the Gates Foundation, indicating a focus on broad access to its therapies [N6].
  • The company has undergone reverse stock splits (1-for-15 in August 2025 and 1-for-12 in March 2026) as part of its corporate actions [S1].
  • There is a regulatory risk related to Nasdaq's new $5 million market value standard for continued listing, which could affect the company's listing status if implemented [S2].
Sources
Sources - Context summary

Generated 2026-11-13

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-04-30 | 10-K/A
  • S2 | 2026-11-12 | 10-Q
Sources - News headlines
  • N1 | 2026-09-29 | www.nasdaq.com | Decoy Therapeutics Reports Preclinical Data For Weekly Intranasal DCOY-CoV | https://www.nasdaq.com/articles/decoy-therapeutics-reports-preclinical-data-weekly-intranasal-dcoy-cov
  • N2 | 2026-09-22 | www.nasdaq.com | Decoy Expands Pan-Filovirus Efforts Through FDA Pathway; Stock Up | https://www.nasdaq.com/articles/decoy-expands-pan-filovirus-efforts-through-fda-pathway-stock
  • N3 | 2026-09-09 | www.nasdaq.com | Clinical Catalysts Drive Biotech Movers: Opus Genetics, Quantum & More | https://www.nasdaq.com/articles/clinical-catalysts-drive-biotech-movers-opus-genetics-quantum-more
  • N4 | 2026-06-30 | www.nasdaq.com | Top Biotech Gainers: UPC Expands Patent Portfolio, All Eyes On SLS, What's Behind The QDEL Rumor? | https://www.nasdaq.com/articles/top-biotech-gainers-upc-expands-patent-portfolio-all-eyes-sls-whats-behind-qdel-rumor
  • N5 | 2026-06-05 | www.nasdaq.com | Weekly Buzz: PHG, KMDA Win FDA Nod; FULC Halts Pociredir; RMD Closes Noctrix Deal; NVS Paces In IgAN | https://www.nasdaq.com/articles/weekly-buzz-phg-kmda-win-fda-nod-fulc-halts-pociredir-rmd-closes-noctrix-deal-nvs-paces
  • N6 | 2026-05-26 | www.nasdaq.com | Top Biotech Gainers: AKTX Rallies; GOVX Up On Ebola Concerns; SLGL Awaits Catalysts; CMMB On Watch | https://www.nasdaq.com/articles/top-biotech-gainers-aktx-rallies-govx-ebola-concerns-slgl-awaits-catalysts-cmmb-watch
  • N7 | 2025-07-14 | www.nasdaq.com | Salarius Pharmaceuticals Receives Extension for Nasdaq Compliance and Updates on Planned Merger with Decoy Therapeutics | https://www.nasdaq.com/articles/salarius-pharmaceuticals-receives-extension-nasdaq-compliance-and-updates-planned-merger
  • N8 | 2025-06-17 | www.nasdaq.com | Salarius Granted Nasdaq Extension To Regain Compliance With Listing Standards | https://www.nasdaq.com/articles/salarius-granted-nasdaq-extension-regain-compliance-listing-standards
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine